Jignesh Shah, MD
Nephrology · Kansas City, MONPI 1871741751
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,700 of the $7,159 with a category attached, or 79.6%. AstraZeneca accounts for 86.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $4,615 and has fallen 60.1% since, to $1,843 in 2024.
Across 35 payments — averaging $204.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Vifor Pharma, Inc.$263
- Mallinckrodt Enterprises LLC$142
- Otsuka America Pharmaceutical, Inc.$114
- GSK$97
- Medtronic$83
- plus $290 from 8 others
What the payments were for
- Speaking & faculty fees$5,70080%
- Travel & lodging$1011%
- Food & beverage$99714%
- Education$3615%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $6,171 |
| Vifor Pharma, Inc. | 3 | $263 |
| Mallinckrodt Enterprises LLC | 4 | $142 |
| Otsuka America Pharmaceutical, Inc. | 2 | $114 |
| GSK | 1 | $97 |
| Medtronic | 1 | $83 |
| Bayer | 3 | $71 |
| Mallinckrodt Hospital Products Inc. | 1 | $66 |
| Amgen | 2 | $52 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Angiodynamics, Inc. | 1 | $26 |
| OPKO Pharmaceuticals, LLC | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $13 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,159 in reported general payments places this provider in the 85th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProcysbiCysteamine Bitartrate | 24 | $172,909 |
| JardianceEmpagliflozin | 52 | $79,509 |
| FarxigaDapagliflozin Propanediol | 85 | $76,632 |
| VelphoroSucroferric Oxyhydroxide | 24 | $45,887 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $13,141 |
| Sevelamer Carbonate | 50 | $10,526 |
| JanuviaSitagliptin Phosphate | 14 | $10,373 |
| Calcium Acetate | 21 | $1,031 |
| Calcitriol | 45 | $810 |
| Spironolactone | 73 | $797 |
| Atorvastatin Calcium | 118 | $747 |
| Hydralazine Hcl | 53 | $695 |
| Potassium Chloride | 28 | $672 |
| Nifedipine ErNifedipine | 34 | $613 |
| Furosemide | 152 | $594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProcysbi | $52 | $172,90924 claims |
| AstraZenecaFarxiga | $6,171 | $76,63285 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 253 nephrology providers in Missouri.
Other nephrology in Kansas City
- Ahmed AwadKansas City$79K
- Richard CaplingKansas City$31K
- Tarek DarwishKansas City$8K
- Adnan KhanKansas City$7K
- Robert GolderKansas City$5K
- Archana GoelKansas City$5K
- Ryan LustigKansas City$4K
- Pranavkumar DalalKansas City$4K
- Rafael TorosyanKansas City$3K
- Derek LarsonCreve Coeur$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.